Aberrant promoter cpg methylation is a mechanism for impaired PHD3 expression in a diverse set of malignant cells

Trenton L. Place, Matthew P. Fitzgerald, Sujatha Venkataraman, Sabine U. Vorrink, Adam J. Case, Melissa L.T. Teoh, Frederick E. Domann

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: The prolyl-hydroxylase domain family of enzymes (PHD1-3) plays an important role in the cellular response to hypoxia by negatively regulating HIF-α proteins. Disruption of this process can lead to up-regulation of factors that promote tumorigenesis. We observed decreased basal expression of PHD3 in prostate cancer tissue and tumor cell lines representing diverse tissues of origin. Furthermore, some cancer lines displayed a failure of PHD3 mRNA induction when introduced to a hypoxic environment. This study explores the mechanism by which malignancies neither basally express PHD3 nor induce PHD3 under hypoxic conditions. Methodology/Principal Findings: Using bisulfite sequencing and methylated DNA enrichment procedures, we identified human PHD3 promoter hypermethylation in prostate, breast, melanoma and renal carcinoma cell lines. In contrast, nontransformed human prostate and breast epithelial cell lines contained PHD3 CpG islands that were unmethylated and responded normally to hypoxia by upregulating PHD3 mRNA. Only treatment of cells lines containing PHD3 promoter hypermethylation with the demethylating drug 5-aza-2′-deoxycytidine significantly increased the expression of PHD3. Conclusions/Significance: We conclude that expression of PHD3 is silenced by aberrant CpG methylation of the PHD3 promoter in a subset of human carcinoma cell lines of diverse origin and that this aberrant cytosine methylation status is the mechanism by which these cancer cell lines fail to upregulate PHD3 mRNA. We further show that a loss of PHD3 expression does not correlate with an increase in HIF-1α protein levels or an increase in the transcriptional activity of HIF, suggesting that loss of PHD3 may convey a selective advantage in some cancers by affecting pathway(s) other than HIF.

Original languageEnglish (US)
Article numbere14617
JournalPloS one
Volume6
Issue number1
DOIs
StatePublished - Feb 7 2011

Fingerprint

Methylation
methylation
Cells
promoter regions
cell lines
Cell Line
decitabine
Messenger RNA
cells
Prostate
Neoplasms
Breast
Up-Regulation
breasts
carcinoma
hypoxia
Tissue
Prolyl Hydroxylases
Carcinoma
procollagen-proline dioxygenase

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Aberrant promoter cpg methylation is a mechanism for impaired PHD3 expression in a diverse set of malignant cells. / Place, Trenton L.; Fitzgerald, Matthew P.; Venkataraman, Sujatha; Vorrink, Sabine U.; Case, Adam J.; Teoh, Melissa L.T.; Domann, Frederick E.

In: PloS one, Vol. 6, No. 1, e14617, 07.02.2011.

Research output: Contribution to journalArticle

Place, Trenton L. ; Fitzgerald, Matthew P. ; Venkataraman, Sujatha ; Vorrink, Sabine U. ; Case, Adam J. ; Teoh, Melissa L.T. ; Domann, Frederick E. / Aberrant promoter cpg methylation is a mechanism for impaired PHD3 expression in a diverse set of malignant cells. In: PloS one. 2011 ; Vol. 6, No. 1.
@article{fa7cabca0571464fa08df7b8a9c44cbc,
title = "Aberrant promoter cpg methylation is a mechanism for impaired PHD3 expression in a diverse set of malignant cells",
abstract = "Background: The prolyl-hydroxylase domain family of enzymes (PHD1-3) plays an important role in the cellular response to hypoxia by negatively regulating HIF-α proteins. Disruption of this process can lead to up-regulation of factors that promote tumorigenesis. We observed decreased basal expression of PHD3 in prostate cancer tissue and tumor cell lines representing diverse tissues of origin. Furthermore, some cancer lines displayed a failure of PHD3 mRNA induction when introduced to a hypoxic environment. This study explores the mechanism by which malignancies neither basally express PHD3 nor induce PHD3 under hypoxic conditions. Methodology/Principal Findings: Using bisulfite sequencing and methylated DNA enrichment procedures, we identified human PHD3 promoter hypermethylation in prostate, breast, melanoma and renal carcinoma cell lines. In contrast, nontransformed human prostate and breast epithelial cell lines contained PHD3 CpG islands that were unmethylated and responded normally to hypoxia by upregulating PHD3 mRNA. Only treatment of cells lines containing PHD3 promoter hypermethylation with the demethylating drug 5-aza-2′-deoxycytidine significantly increased the expression of PHD3. Conclusions/Significance: We conclude that expression of PHD3 is silenced by aberrant CpG methylation of the PHD3 promoter in a subset of human carcinoma cell lines of diverse origin and that this aberrant cytosine methylation status is the mechanism by which these cancer cell lines fail to upregulate PHD3 mRNA. We further show that a loss of PHD3 expression does not correlate with an increase in HIF-1α protein levels or an increase in the transcriptional activity of HIF, suggesting that loss of PHD3 may convey a selective advantage in some cancers by affecting pathway(s) other than HIF.",
author = "Place, {Trenton L.} and Fitzgerald, {Matthew P.} and Sujatha Venkataraman and Vorrink, {Sabine U.} and Case, {Adam J.} and Teoh, {Melissa L.T.} and Domann, {Frederick E.}",
year = "2011",
month = "2",
day = "7",
doi = "10.1371/journal.pone.0014617",
language = "English (US)",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Aberrant promoter cpg methylation is a mechanism for impaired PHD3 expression in a diverse set of malignant cells

AU - Place, Trenton L.

AU - Fitzgerald, Matthew P.

AU - Venkataraman, Sujatha

AU - Vorrink, Sabine U.

AU - Case, Adam J.

AU - Teoh, Melissa L.T.

AU - Domann, Frederick E.

PY - 2011/2/7

Y1 - 2011/2/7

N2 - Background: The prolyl-hydroxylase domain family of enzymes (PHD1-3) plays an important role in the cellular response to hypoxia by negatively regulating HIF-α proteins. Disruption of this process can lead to up-regulation of factors that promote tumorigenesis. We observed decreased basal expression of PHD3 in prostate cancer tissue and tumor cell lines representing diverse tissues of origin. Furthermore, some cancer lines displayed a failure of PHD3 mRNA induction when introduced to a hypoxic environment. This study explores the mechanism by which malignancies neither basally express PHD3 nor induce PHD3 under hypoxic conditions. Methodology/Principal Findings: Using bisulfite sequencing and methylated DNA enrichment procedures, we identified human PHD3 promoter hypermethylation in prostate, breast, melanoma and renal carcinoma cell lines. In contrast, nontransformed human prostate and breast epithelial cell lines contained PHD3 CpG islands that were unmethylated and responded normally to hypoxia by upregulating PHD3 mRNA. Only treatment of cells lines containing PHD3 promoter hypermethylation with the demethylating drug 5-aza-2′-deoxycytidine significantly increased the expression of PHD3. Conclusions/Significance: We conclude that expression of PHD3 is silenced by aberrant CpG methylation of the PHD3 promoter in a subset of human carcinoma cell lines of diverse origin and that this aberrant cytosine methylation status is the mechanism by which these cancer cell lines fail to upregulate PHD3 mRNA. We further show that a loss of PHD3 expression does not correlate with an increase in HIF-1α protein levels or an increase in the transcriptional activity of HIF, suggesting that loss of PHD3 may convey a selective advantage in some cancers by affecting pathway(s) other than HIF.

AB - Background: The prolyl-hydroxylase domain family of enzymes (PHD1-3) plays an important role in the cellular response to hypoxia by negatively regulating HIF-α proteins. Disruption of this process can lead to up-regulation of factors that promote tumorigenesis. We observed decreased basal expression of PHD3 in prostate cancer tissue and tumor cell lines representing diverse tissues of origin. Furthermore, some cancer lines displayed a failure of PHD3 mRNA induction when introduced to a hypoxic environment. This study explores the mechanism by which malignancies neither basally express PHD3 nor induce PHD3 under hypoxic conditions. Methodology/Principal Findings: Using bisulfite sequencing and methylated DNA enrichment procedures, we identified human PHD3 promoter hypermethylation in prostate, breast, melanoma and renal carcinoma cell lines. In contrast, nontransformed human prostate and breast epithelial cell lines contained PHD3 CpG islands that were unmethylated and responded normally to hypoxia by upregulating PHD3 mRNA. Only treatment of cells lines containing PHD3 promoter hypermethylation with the demethylating drug 5-aza-2′-deoxycytidine significantly increased the expression of PHD3. Conclusions/Significance: We conclude that expression of PHD3 is silenced by aberrant CpG methylation of the PHD3 promoter in a subset of human carcinoma cell lines of diverse origin and that this aberrant cytosine methylation status is the mechanism by which these cancer cell lines fail to upregulate PHD3 mRNA. We further show that a loss of PHD3 expression does not correlate with an increase in HIF-1α protein levels or an increase in the transcriptional activity of HIF, suggesting that loss of PHD3 may convey a selective advantage in some cancers by affecting pathway(s) other than HIF.

UR - http://www.scopus.com/inward/record.url?scp=79551563597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551563597&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0014617

DO - 10.1371/journal.pone.0014617

M3 - Article

C2 - 21297970

AN - SCOPUS:79551563597

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e14617

ER -